Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for the sale of its entire interest (the “Interest”) in STEM Animal Health Inc. (“STEM”) to a third party multi-national pharmaceutical company (the “Purchaser”) on a cash-free debt-free basis for US $8,000,000 (the “Transaction”), subject to adjustments in accordance with the terms of the agreement in principle, as well as other consideration including the net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000). Overall, it is anticipated that the sale of STEM Animal Health will net Kane Biotech in excess of CND $11,500,000 (including the cash deposits already received, as noted below). The Purchaser is not a Non-Arm’s Length Party (as that term is defined by the TSX Venture Exchange) of the Company.
Related news for (KNBIF)
- Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
- Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
- Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
- Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
- Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel